Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACZ885 plus pembrolizumab + platinum chemotherapy vs placebo in first-line advanced NSCLC
CTR20191394Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of canakinumab in non-small cell lung cancer (NSCLC), sponsored by Novartis. Started Jul 2019; status: terminated.
02
Drugs
canakinumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20191394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191394.